Galmed's Aramchol misses in Phase IIa for HIV-associated NAFLD

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) said Aramchol arachidyl amino cholanoic acid missed the primary endpoint in the Phase IIa ARRIVE

Read the full 199 word article

User Sign In